Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20738728 | 0.89 | HDAC3 (0.54) | MTNR1AMTNR1BSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL8460016 | 0.84 | MTNR1A (0.50) | MTNR1AMTNR1BALDH1A1GAA | |
| SCHEMBL30849698 | 0.84 | MTNR1A (0.69) | MTNR1AMTNR1BALDH1A1GAAHPGD | |
| SCHEMBL5597754 | 0.83 | CA1 (0.55) | SMN1; SMN2POLBALDH1A1GAAHPGD | |
| SCHEMBL4856579 | 0.83 | MTNR1A (0.49) | MTNR1AMTNR1BPOLBALDH1A1GAA | |
| SCHEMBL8644052 | 0.83 | ALDH1A1 (0.61) | SMN1; SMN2POLBALDH1A1GAAHPGD | |
| SCHEMBL20738591 | 0.83 | SETDB1 (0.53) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL4329523 | 0.81 | CNR1 (0.45) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL885000 | 0.81 | MTNR1A (0.71) | MTNR1AMTNR1BSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL8343069 | 0.81 | LMNA (0.53) | MTNR1AMTNR1BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MTNR1A 823/4885MTNR1B 815/4885SMN1; SMN2 2550/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MTNR1A 823/4885MTNR1B 815/4885SMN1; SMN2 2550/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | MTNR1A 773/4885MTNR1B 747/4885SMN1; SMN2 2671/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | MTNR1A 823/4885MTNR1B 815/4885SMN1; SMN2 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.